- Harvoni®’s overall established cure rate in patients with HCV genotype 1, 4, 5 and 6 is roughly 92%
- Harvoni® is not suitable for patients with genotypes 2 or 3. If patients did not get a genotype test, they should be treated with Epclusa® instead
- For treatment experienced patients or those with advanced Liver cirrhosis (decompensated), treatment duration is 24 weeks instead of 12 weeks
- Harvoni®’s side effects profile is quite mild especially with enough water intake
- Consult a doctor before concurrent administration of other drugs or supplements to avoid drug interactions
- Harvoni® is approved by the FDA and EMA for use in adults and children aged 3 years and older
- You can visit the FixHepC forum for more information about Hepatitis C treatment
Please refer to the originator’s website to learn all the information needed to use this medicine safely and effectively.
Reviews
There are no reviews yet.